Litigation Details for AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2017)
✉ Email this page to a colleague
AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-11-12 |
| Court | District Court, D. Delaware | Date Terminated | 2019-01-01 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ASTRAZENECA UK LIMITED | ||
| Patents | 6,251,910; 6,525,060; 7,250,419; 7,265,124; RE46,276 | ||
| Attorneys | Daniel M. Silver | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca LP v. Prinston Pharmaceutical Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-11-12 | 1 | AstraZeneca’s U.S. Patent Nos. 6,251,910 (“the ’910 patent”), RE 46,276 (“the ’276 patent”), 7,250,419 (…issued the ’276 patent, a reissue of the ’060 patent, which now replaces the ’060 patent in suit. A true… This is an action for patent infringement arising under the patent laws of the United States, … (“the ’419 patent”), and 7,265,124 (“the ’124 patent”) that are listed in the Approved Drug Products… PATENTS-IN-SUIT 23. On June 26, 2001, the U.S. Patent and Trademark Office | External link to document | |
| 2019-01-02 | 15 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; RE46,276; 7,250,419…2017 2 January 2019 1:17-cv-01639 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2017-11-12 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; RE46,276; 7,250,419…2017 2 January 2019 1:17-cv-01639 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
